Clin2
NCT07603466Likely a fitEnrolling by invitation

Two drugs combined to treat Cushing's disease

Cushing Disease Due to Increased ACTH Secretion

Treatments studied

Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests whether taking two medications together—osilodrostat and cabergoline—can help control Cushing's disease by lowering excess cortisol levels. Cushing's disease is caused by a pituitary tumor that makes too much of a hormone called ACTH, which drives cortisol overproduction.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
50 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You have Cushing's disease that is either untreated or has been treated with surgery and/or radiation
  • Your Cushing's disease is currently active (confirmed by two separate blood and saliva cortisol tests)
  • Blood tests show you have elevated ACTH hormone levels
  • A special hormone stimulation test (desmopressin) shows your pituitary responds abnormally
  • An MRI scan shows you have a pituitary tumor (adenoma)
  • You do not have severe liver damage and are not pregnant

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06430528Recruiting
Osilodrostat and steroid replacement for Cushing syndrome

This trial tests a new approach, called 'block-and-replace', for treating Cushing syndrome. You will take osilodrostat to lower high cortisol levels, along with a glucocorticoid (a steroid) to replace what your body needs. This study may help control the disease if surgery hasn't worked or isn't an option.

Ann Arbor, Michigan
NCT07247162Not yet recruiting· Phase 4
A study on osilodrostat for high blood pressure caused by Cushing's syndrome

This trial tests whether osilodrostat can lower blood pressure in people with Cushing's syndrome whose high blood pressure is not well controlled by their current medications. The drug works by reducing the production of the stress hormone cortisol, which is abnormally high in Cushing's syndrome.

NCT03708900Recruiting· Phase 2
Osilodrostat study for children with Cushing’s syndrome

This Phase 2 study tests how osilodrostat works in children and teens with Cushing’s syndrome—what the drug does in the body, how it affects hormones, and how safely it’s tolerated. It may help families who cannot have immediate surgery or whose surgery has already failed or is still pending.

San Francisco, California
NCT06701838Not yet recruiting
Osilodrostat and PET scan for Cushing's disease

This trial tests whether a medication (osilodrostat) combined with a special PET scan can help find tiny pituitary tumors in people with Cushing's disease when MRI shows nothing or something unclear. It may help guide surgery or other treatments.

NCT05971758Recruiting· Phase 2
Test drug treatment for pituitary Cushing disease

This Phase 2 trial tests fimepinostat (a targeted cancer-style drug) to help control Cushing disease caused by a pituitary tumor. It’s mainly for adults whose Cushing is confirmed to come from the pituitary and who meet safety and medication-washout rules.

Los Angeles, California
NCT03774446Recruiting· Phase 2
Seliciclib trial for Cushing disease from a pituitary tumor

This Phase 2 study tests seliciclib (also called R-roscovitine) in people with Cushing disease caused by a pituitary tumor and ongoing high cortisol levels. It may help reduce excess cortisol production in those whose Cushing disease has not fully gone away or has come back after standard treatment.

Los Angeles, California

Hear when a new Cushing Disease Due to Increased ACTH Secretion trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.